Abstract
This article provides an update on the diagnosis and management of the antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides, granulomatosis with polyangiitis (formerly Wegener), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss). Focus is on new schemes of classification and the importance of ANCAs in the diagnosis and prognosis of these systemic vasculitides. Current therapeutic strategies consisting of glucocorticoids in conjunction with conventional or biologic agents for both induction of remission and remission maintenance are outlined. Future research directions include investigation of the optimal duration and frequency of maintenance therapy and development of targeted therapeutic agents.
Keywords:
ANCA-associated vasculitis; Eosinophilic granulomatosis with polyangiitis (Churg-Strauss); Granulomatosis with polyangiitis (Wegener); Microscopic polyangiitis.
MeSH terms
-
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / classification
-
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / diagnosis
-
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / drug therapy*
-
Antibodies, Antineutrophil Cytoplasmic / immunology
-
Autoantibodies / immunology
-
Churg-Strauss Syndrome / classification
-
Churg-Strauss Syndrome / diagnosis
-
Churg-Strauss Syndrome / drug therapy
-
Enzyme-Linked Immunosorbent Assay
-
Glucocorticoids / therapeutic use*
-
Granulomatosis with Polyangiitis / classification
-
Granulomatosis with Polyangiitis / diagnosis
-
Granulomatosis with Polyangiitis / drug therapy
-
Humans
-
Immunosuppressive Agents / therapeutic use*
-
Maintenance Chemotherapy / methods
-
Microscopic Polyangiitis / classification
-
Microscopic Polyangiitis / diagnosis
-
Microscopic Polyangiitis / drug therapy
-
Myeloblastin / immunology
-
Peroxidase / immunology
-
Remission Induction / methods
Substances
-
Antibodies, Antineutrophil Cytoplasmic
-
Autoantibodies
-
Glucocorticoids
-
Immunosuppressive Agents
-
Peroxidase
-
Myeloblastin